Retractable Technologies Reports 15.8% Revenue Increase to $38.3 Million Despite Net Loss

Retractable Technologies, Inc. reported a revenue increase of 15.8% for the fiscal year ending December 31, 2025, totaling $38.3 million, compared to $33.0 million in 2024. The company's domestic sales accounted for 84.2% of total revenues, reflecting a 9.7% increase driven by higher sales of its VanishPoint® and EasyPoint® needle products. International sales surged by 64.0%, primarily due to a significant rise in EasyPoint® needle sales, although revenue growth was tempered by discounted pricing on international units. Despite the revenue growth, the company recorded a net loss of $12.6 million, slightly higher than the $11.9 million loss in the previous year.

The company faced significant challenges due to tariffs imposed on imported goods, particularly syringes and needles from China, which were subject to a 120% tariff as of March 2026. In 2025, Retractable Technologies incurred approximately $1.8 million in tariff expenses, which contributed to a gross profit margin increase from -3.1% in 2024 to 0.1% in 2025. The company has been actively working to mitigate the impact of these tariffs by increasing domestic manufacturing capacity, particularly for its 1mL, 3mL, and EasyPoint® needles, and reducing reliance on imports.

Operationally, the company reported a total employee count of 201 as of March 2026, with 195 being full-time employees. The workforce has become increasingly vital as the company shifts production to domestic facilities in response to tariff pressures. The company has also expanded its manufacturing capabilities through a Technology Investment Agreement with the U.S. government, which funded a significant portion of its facility upgrades and equipment purchases. This agreement is set to continue until June 30, 2030, ensuring government preference in the event of a public health emergency.

Looking ahead, Retractable Technologies anticipates ongoing challenges related to market conditions, including fluctuating demand for syringes as customers may have retained excess inventory from previous vaccination efforts. The company is also developing new safety products, although none are expected to be commercially available in 2026. The management remains cautious about future revenue growth, particularly in light of the uncertainties surrounding public sentiment towards vaccinations and the potential impact of tariffs on sourcing and production costs. The company is committed to enhancing its domestic production capabilities to better position itself in the market while navigating these challenges.